» Articles » PMID: 21835188

Magnesium Deficiency Induces Anxiety and HPA Axis Dysregulation: Modulation by Therapeutic Drug Treatment

Overview
Specialties Neurology
Pharmacology
Date 2011 Aug 13
PMID 21835188
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Preclinical and some clinical studies suggest a relationship between perturbation in magnesium (Mg(2+)) homeostasis and pathological anxiety, although the underlying mechanisms remain largely unknown. Since there is evidence that Mg(2+) modulates the hypothalamic-pituitary adrenal (HPA) axis, we tested whether enhanced anxiety-like behaviour can be reliably elicited by dietary Mg(2+) deficiency and whether Mg(2+) deficiency is associated with altered HPA axis function. Compared with controls, Mg(2+) deficient mice did indeed display enhanced anxiety-related behaviour in a battery of established anxiety tests. The enhanced anxiety-related behaviour of Mg(2+) deficient mice was sensitive to chronic desipramine treatment in the hyponeophagia test and to acute diazepam treatment in the open arm exposure test. Mg(2+) deficiency caused an increase in the transcription of the corticotropin releasing hormone in the paraventricular hypothalamic nucleus (PVN), and elevated ACTH plasma levels, pointing to an enhanced set-point of the HPA axis. Chronic treatment with desipramine reversed the identified abnormalities of the stress axis. Functional mapping of neuronal activity using c-Fos revealed hyper-excitability in the PVN of anxious Mg(2+) deficient mice and its normalisation through diazepam treatment. Overall, the present findings demonstrate the robustness and validity of the Mg(2+) deficiency model as a mouse model of enhanced anxiety, showing sensitivity to treatment with anxiolytics and antidepressants. It is further suggested that dysregulations in the HPA axis may contribute to the hyper-emotionality in response to dietary induced hypomagnesaemia. This article is part of a Special Issue entitled 'Anxiety and Depression'.

Citing Articles

Micronutrient interactions: Magnesium and its synergies in maternal-fetal health.

Shukla V, Parvez S, Fatima G, Singh S, Magomedova A, El-Saber Batiha G Food Sci Nutr. 2024; 12(10):6913-6928.

PMID: 39479677 PMC: 11521725. DOI: 10.1002/fsn3.4316.


Magnesium (Mg): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation.

Kumar A, Mehan S, Tiwari A, Khan Z, Gupta G, Narula A Curr Pharm Des. 2024; 30(39):3074-3107.

PMID: 39253923 DOI: 10.2174/0113816128321466240816075041.


Progress and trends of research on mineral elements for depression.

Gao B, Li C, Qu Y, Cai M, Zhou Q, Zhang Y Heliyon. 2024; 10(15):e35469.

PMID: 39170573 PMC: 11336727. DOI: 10.1016/j.heliyon.2024.e35469.


Examining the Effects of Supplemental Magnesium on Self-Reported Anxiety and Sleep Quality: A Systematic Review.

Rawji A, Peltier M, Mourtzanakis K, Awan S, Rana J, Pothen N Cureus. 2024; 16(4):e59317.

PMID: 38817505 PMC: 11136869. DOI: 10.7759/cureus.59317.


The Association Between Children's Dietary Inflammatory Index (C-DII) and Nutrient Adequacy with Gastrointestinal Symptoms, Sleep Habits, and Autistic Traits.

Zare M, Ahmadi A, Dehbozorgi S, Zare M, Hejazi N J Autism Dev Disord. 2024; .

PMID: 38607471 DOI: 10.1007/s10803-024-06328-z.


References
1.
Muigg P, Scheiber S, Salchner P, Bunck M, Landgraf R, Singewald N . Differential stress-induced neuronal activation patterns in mouse lines selectively bred for high, normal or low anxiety. PLoS One. 2009; 4(4):e5346. PMC: 2670503. DOI: 10.1371/journal.pone.0005346. View

2.
Bodnoff S, Aitken D, Quirion R, Meaney M . The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl). 1988; 95(3):298-302. DOI: 10.1007/BF00181937. View

3.
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S . Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003; 301(5634):805-9. DOI: 10.1126/science.1083328. View

4.
Singewald N, Salchner P, Sharp T . Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry. 2003; 53(4):275-83. DOI: 10.1016/s0006-3223(02)01574-3. View

5.
Lowry C, Moore F . Regulation of behavioral responses by corticotropin-releasing factor. Gen Comp Endocrinol. 2006; 146(1):19-27. DOI: 10.1016/j.ygcen.2005.12.006. View